NO20033341D0 - Metoder for administrering av epothilone-analoger for behandling av kreft - Google Patents

Metoder for administrering av epothilone-analoger for behandling av kreft

Info

Publication number
NO20033341D0
NO20033341D0 NO20033341A NO20033341A NO20033341D0 NO 20033341 D0 NO20033341 D0 NO 20033341D0 NO 20033341 A NO20033341 A NO 20033341A NO 20033341 A NO20033341 A NO 20033341A NO 20033341 D0 NO20033341 D0 NO 20033341D0
Authority
NO
Norway
Prior art keywords
cancer
treatment
methods
epothilone analogues
administering epothilone
Prior art date
Application number
NO20033341A
Other languages
English (en)
Other versions
NO335119B1 (no
NO20033341L (no
Inventor
Rebanta Bandyopadhyay
Timothy M Malloy
Andrea Panaggio
Krishnaswamy Srinivas Raghavan
Sailesh Amilal Varia
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20033341D0 publication Critical patent/NO20033341D0/no
Publication of NO20033341L publication Critical patent/NO20033341L/no
Publication of NO335119B1 publication Critical patent/NO335119B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20033341A 2001-01-25 2003-07-24 Fremgangsmåte for formulering av en epothilone-analog for parenteral administrering, farmasøytisk blanding omfattende slike samt denne forbindelsen for behandling av kreft NO335119B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26422801P 2001-01-25 2001-01-25
US29000601P 2001-05-11 2001-05-11
PCT/US2002/001813 WO2002058700A1 (en) 2001-01-25 2002-01-22 Methods of administering epothilone analogs for the treatment of cancer

Publications (3)

Publication Number Publication Date
NO20033341D0 true NO20033341D0 (no) 2003-07-24
NO20033341L NO20033341L (no) 2003-09-04
NO335119B1 NO335119B1 (no) 2014-09-22

Family

ID=26950348

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20033341A NO335119B1 (no) 2001-01-25 2003-07-24 Fremgangsmåte for formulering av en epothilone-analog for parenteral administrering, farmasøytisk blanding omfattende slike samt denne forbindelsen for behandling av kreft

Country Status (10)

Country Link
JP (1) JP4633331B2 (no)
AU (1) AU2002245296B2 (no)
CA (1) CA2434526C (no)
HR (1) HRP20030677B1 (no)
IL (1) IL156578A0 (no)
MX (1) MXPA03006412A (no)
NO (1) NO335119B1 (no)
PL (1) PL207720B1 (no)
RU (1) RU2292202C2 (no)
WO (1) WO2002058700A1 (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867305B2 (en) 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
WO1999001124A1 (en) 1996-12-03 1999-01-14 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US8618085B2 (en) * 2000-04-28 2013-12-31 Koasn Biosciences Incorporated Therapeutic formulations of desoxyepothilones
NZ526871A (en) 2001-01-25 2006-01-27 Bristol Myers Squibb Co Pharmaceutical dosage forms of epothilones for oral administration
AU2008200555C1 (en) * 2003-03-14 2011-12-15 Novartis Ag Treatment of proliferative diseases with epothilone derivatives and radiation
GB0305928D0 (en) * 2003-03-14 2003-04-23 Novartis Ag Organic compounds
EP1674098A1 (en) * 2004-12-23 2006-06-28 Schering Aktiengesellschaft Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
EP2478905B1 (en) * 2007-06-01 2014-05-14 Wyeth LLC Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles
WO2009089138A1 (en) * 2008-01-04 2009-07-16 Bristol-Myers Squibb Company Oral administration of ixabepilone

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW406020B (en) * 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
US5681846A (en) * 1995-03-17 1997-10-28 Board Of Regents, The University Of Texas System Extended stability formulations for paclitaxel
WO1999001124A1 (en) * 1996-12-03 1999-01-14 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6605599B1 (en) * 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
DE69802536T2 (de) * 1997-07-18 2002-05-23 Hewlett Packard Co Format zum informationstransfer zwischen geräten
US6365749B1 (en) * 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
TW457095B (en) * 1998-02-05 2001-10-01 Novartis Ag Pharmaceutical formulations comprising epothilones and lyophilised compositions comprising epothilones
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6399638B1 (en) * 1998-04-21 2002-06-04 Bristol-Myers Squibb Company 12,13-modified epothilone derivatives
ES2291194T3 (es) * 1999-02-18 2008-03-01 Bayer Schering Pharma Aktiengesellschaft Derivados de 16-halogeno-epotilones, procedimiento acerca de su preparacion y su utilizacion farmaceutica.
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon

Also Published As

Publication number Publication date
NO335119B1 (no) 2014-09-22
AU2002245296B2 (en) 2006-12-21
CA2434526C (en) 2011-11-01
HRP20030677B1 (en) 2011-10-31
HRP20030677A2 (en) 2004-08-31
WO2002058700A1 (en) 2002-08-01
RU2003126170A (ru) 2005-02-27
PL373727A1 (en) 2005-09-05
JP4633331B2 (ja) 2011-02-16
NO20033341L (no) 2003-09-04
PL207720B1 (pl) 2011-01-31
MXPA03006412A (es) 2003-10-15
IL156578A0 (en) 2004-01-04
CA2434526A1 (en) 2002-08-01
JP2005503323A (ja) 2005-02-03
RU2292202C2 (ru) 2007-01-27

Similar Documents

Publication Publication Date Title
CY2019030I2 (el) Παραγωγο ραπαμυκινης για την θεραπευτικη αντιμετωπιση του καρκινου του πνευμονα
IS6891A (is) Aðferðir við gjöf epóþílon hliðstæðna við meðferðkrabbameins
ZA200305126B (en) Methods of administering epothilone analogs for the treatment of cancer.
EE05481B1 (et) Kinasoliini derivaadid kasvajate raviks
IS7691A (is) Lyfjasamsetningar til að meðhöndla æxli
NO20052894D0 (no) 4-tetrazolyl-4-fenylpiperidin-derivater for behandling av smerte
CY2015003I1 (el) Φαρμακευτικες συνθεσεις για θεραπεια καρκινου
CY2014019I1 (el) Παραγωγα φαιναιθανολαμινης για θεραπεια ασθενειων του αναπνευστικου
IS6917A (is) Epóþílon afleiður til meðhöndlunar erfiðra æxla
NO20033594D0 (no) Fenetanolamin-derivater for behandling av luftveissykdommer
NO20053077D0 (no) Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
NO20040516L (no) Kombinasjonsterapi for behandling av kreft.
IS8398A (is) Lyfjasamsetningar til að meðhöndla æxli
IS8125A (is) Kínasólínafleiður til að meðhöndla krabbamein
EE200300396A (et) Epotilooni derivaatide kasutamine refraktaarsete kasvajate raviks
NO20034780L (no) Antiangiogenisk kombinasjonsterapi for behandling av kreft
HUP0400314A3 (en) Pharmaceutical combinations for the treatment of cancer
NO20020358D0 (no) Anvendelse av etodolac for behandling av kreft
NO20034123L (no) Fremgangsmåte for behandling av brennstoff
NO20033804D0 (no) Karbamatforbindelser for behandling av smerte
NO20033341D0 (no) Metoder for administrering av epothilone-analoger for behandling av kreft
NO20024776L (no) Hydroksyfenyl-piperazinyl-metyl-benzamid derivater til behandling av smerte
NO20024777L (no) Kinolinyl-piperidin-4-yliden-metyl-benzamid derivater til behandling av smerte
NO20020784L (no) Medikament for behandling av brudd
NO20042476L (no) Anvendelse av desoxypeganin for behandling av klinisk depresjon

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: R-PHARM US OPERATING, US

MM1K Lapsed by not paying the annual fees